(Total Views: 394)
Posted On: 02/22/2019 2:30:21 AM
Post# of 15624
Hi Gary,
The latest shareholder letter does provide some guidance.
"With respect to our timeline going forward, key upcoming events include the following:
Our comparative safety and efficacy trial for our tablet will be initiated in the second quarter of 2019. This duration of this trial is expected to be four month.
The efficacy trial for our cannabis cream will also be initiated in the third quarter 2019. This duration of this trial is expected to be approximately 24 months."
The cream is 2 years ago from revenue. How comfortable are you with their plan to completing the tablet trail in 4 months? They have intention of seeking approval to export it.
The latest shareholder letter does provide some guidance.
"With respect to our timeline going forward, key upcoming events include the following:
Our comparative safety and efficacy trial for our tablet will be initiated in the second quarter of 2019. This duration of this trial is expected to be four month.
The efficacy trial for our cannabis cream will also be initiated in the third quarter 2019. This duration of this trial is expected to be approximately 24 months."
The cream is 2 years ago from revenue. How comfortable are you with their plan to completing the tablet trail in 4 months? They have intention of seeking approval to export it.
(0)
(0)
